TD Asset Management
RGLS

TD Asset Management’s Regulus Therapeutics RGLS Stock Holding History

TD Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-302,000
Closed -$486K – 1382
2024
Q3 		$486K Buy
+302,000
New +$500K ﹤0.01% 1302

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Asset Management's RGLS Position: Q4 2024 in Review

TD Asset Management sold out of Regulus Therapeutics (RGLS) in Q4 2024, closing a stake of 302,000 shares — an estimated $486K sold.

TD Asset Management first reported a position in RGLS in Q3 2024 and held it in 1 quarter. The position peaked at $486K in Q3 2024. 69 funds tracked by Wall St. Rank hold RGLS as of Q4 2024.

  • TD Asset Management reported no remaining Regulus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • TD Asset Management sold 302,000 Regulus Therapeutics shares in Q4 2024, an estimated $486K.
  • TD Asset Management first reported a position in Regulus Therapeutics in Q3 2024 and held it in 1 quarter.
  • TD Asset Management's Regulus Therapeutics position peaked at $486K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2024.

Based on TD Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.